Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the most effective dose of Targretin®
(bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The
safety and tolerability of this drug will also be studied.
Objectives:
1. Determine the safety and tolerability of Targretin® Gel 1% in the treatment of patients
with alopecia areata.
2. Determine the efficacy of Targretin® Gel 1% in the treatment of patients with alopecia
areata.